Emergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?

References

• Miravitlles M, Soriano JB, García-Río F, et al.Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64(10):863–868.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123(3):784–791.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martínez MA, Román P, et al.Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy fort he diagnosis, management, and prevention of COPD. 2007. Available from: http://www.goldcopd.com (accessed).
   Google Scholar
• Asche C, Leader S, Plauschinat C, et al.Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2012; 7:201–209.
   PubMed Web of Science ®Google Scholar
• Mularski RA, Asch SM, Shrank WH, et al.The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest 2006; 130(6):1844–1850.
   PubMed Web of Science ®Google Scholar
• Quintana JM, Esteban C., Barrio I, et al.The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort. BMC Health Serv Res 2011; 11:322.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40(5):373–383.
   PubMedGoogle Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581–586.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Troosters T, Celli B, Lystig T, et al.Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36(1):65–73.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al.Tiotropium vs salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364(12):1093–1103.
   PubMed Web of Science ®Google Scholar
• Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD009157.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Davis KJ, Coleman B, et al.The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124(2):474–481.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64(8):728–735.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Andreu I, Romero Y, et al.Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract 2012; 62(595):e68–75.
   PubMed Web of Science ®Google Scholar
• Van Noord J, Aumann J, Janssens E, et al.Combining tiotropium and salmeterol in COPD: Effects on air flow obstruction and symptoms. Respir Med 2010; 104(7):995–1004.
   PubMed Web of Science ®Google Scholar
• Mezzi K, Pallante J, Alagappan V, et al.Once-Daily QVA149 Demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE Study. Chest 2014; 145:424A.
   PubMed Web of Science ®Google Scholar
• Wedzicha J, Ficker J, Niewohner D, et al.Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: the SPARK Study. Chest 2014; 145:406A.
   Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Decramer M, Hanania N, Lötvall J, Yawn B. The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013; 8:53–64.
   PubMed Web of Science ®Google Scholar
• Dault R, Dubé A, Blais L, et al.Management of chronic obstructive pulmonary disease in patients admitted to a tertiary care center for exacerbation of their disease. Can J Hosp Pharm 2012; 65(5):373–379.
   PubMedGoogle Scholar
• Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001; 18(6):903–908.
   PubMed Web of Science ®Google Scholar
• De Miguel J, Izquierdo JL, Rodríguez JM, et al.Drug treatment of Chronic Obstructive Pulmonary Disease on two levels of patient care: degree of compliance with recommended protocols. Arch Bronconeumol 2003; 39(5):195–202.
   PubMed Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, et al.Overtreatment of COPD with inhaled corticosteroids – Implications for safety and costs: Cross-sectional observational study. Plos One 2013; 8(10):e75221.
   PubMed Web of Science ®Google Scholar
• Asche C, Leader S, Plauschinat C, et al.Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2012; 7:201–209.
   PubMed Web of Science ®Google Scholar
• Kozma C, Paris A, Plauschinat C, et al.Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study. BMC Pulmon Med 2011; 11:61.
   PubMed Web of Science ®Google Scholar